Innotive Diagnostics

What Innotive Diagnostics does

Innotive Diagnostics (InnotiveDx) is a UK-based point-of-care diagnostic medical device company developing the InnotiveUTI system, which delivers bacterial identification and antimicrobial susceptibility testing (AST) results within 60 minutes at the point of care, eliminating the 24-48+ hour wait associated with traditional laboratory culture methods. The technology platform combines proprietary rapid-growth bacterial media, single-use cartridges that isolate bacteria into a monolayer, automated microscopy imaging every 10 minutes over a one-hour period, fluorescent dye-based spectral fingerprinting, and a proprietary image analysis algorithm for bacterial enumeration and ID. Benchtop validation has demonstrated 97% bacterial ID accuracy versus third-party laboratory systems, 100% AST agreement with the CLSI M07 agar dilution gold standard (N=391 samples), and greater than 96% benchtop assay accuracy in blinded evaluations.

The company serves healthcare providers—primarily primary care physicians and emergency department clinicians—who currently prescribe antibiotics empirically due to the absence of rapid point-of-care diagnostics. End beneficiaries are predominantly female UTI patients (71%+ of sufferers) who currently endure delayed or inaccurate diagnoses. The intended revenue model is a razor-and-blade hardware-plus-consumable structure: instrument placement with recurring single-use cartridge sales, typical for point-of-care diagnostics, though no public pricing has been disclosed. InnotiveDx has not yet received approval or clearance from any regulatory authority and remains pre-revenue.

The company was founded in 2021 as a spinout from the Universities of Liverpool and Manchester, initially operating as PhenUtest Diagnostics before rebranding in November 2024 alongside its Series A round. To date, InnotiveDx has raised £3.2m in seed funding (March 2024), an undisclosed Series A (November 2024), and a £1m grant from PACE (November 2025). It is pursuing US market entry via the Texas Medical Center Innovation Accelerator and has been longlisted for the Nature Spinoff Prize and recognized as a Healthtech Challenger Award finalist.

Name

Innotive Diagnostics

Legal name

Innotive Diagnostics

Website

https://innotivedx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Innotive Diagnostics (InnotiveDx) is a UK-based medtech company developing the InnotiveUTI point-of-care diagnostic system, which delivers bacterial identification and antimicrobial susceptibility results within 60 minutes for healthcare providers currently reliant on empirical antibiotic prescribing for urinary tract infections.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)

akta.pro secondary industries

Urinalysis & Routine Screening Diagnostics (HLAHAAAG), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

Keywords

• Point-of-care diagnostics
• UTI diagnostic systems
• Antimicrobial susceptibility testing
• Rapid bacterial identification
• In vitro diagnostics

Headquarters

HQ city

Bath

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. InnotiveUTI Diagnostic System: Medical device company developing a rapid UTI diagnostic system with proprietary instruments and single-use cartridges. Revenue model likely consists of instrument sales and recurring cartridge/consumable revenue, typical for point-of-care diagnostics companies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Innotive Diagnostics manufactures a point-of-care diagnostic system (InnotiveUTI) for urinary tract infections, consisting of a proprietary benchtop instrument paired with single-use cartridges. The system uses proprietary growth media, automated microscopy, and spectral fingerprinting to deliver bacterial identification and antimicrobial susceptibility testing results within 60 minutes directly at the point of care, without requiring a laboratory.

Product overview

Innotive Diagnostics (InnotiveDx) offers a single unified product—the InnotiveUTI diagnostic system—which combines hardware (instrument and cartridge) with a proprietary assay to perform rapid point-of-care UTI testing. The system provides enumeration, causative bacterial identification, and antimicrobial susceptibility testing within 60 minutes directly at the point of care, without requiring a laboratory. The technology is based on cutting-edge research from the universities of Liverpool and Manchester, utilizing proprietary growth media and image analysis algorithms.

Differentiator

Problem solved

Functional benefit

Brands

• InnotiveUTI: Point-of-care rapid urinary tract infection (UTI) diagnostic test that provides accurate results within one hour, including bacterial ID and antimicrobial susceptibility testing.

Products and services

• InnotiveUTI Point-of-care urinary tract infection diagnostic system that combines a proprietary benchtop instrument with single-use cartridges to deliver accurate bacterial identification and antimicrobial susceptibility test (AST) results within 60 minutes, targeting uncomplicated UTIs in primary care, emergency departments, and clinics to prevent misprescribed antibiotics and counter antimicrobial resistance.

Quantifiable outcome

• Bacterial ID accuracy of 97% compared to 3rd party laboratory system
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Texas Medical Center Innovation (TMCi)coreStrategic or Co-development Partner · 31 May 2024InnotiveDx was selected as one of eight UK-based medical device companies to join the second cohort of the Texas Medical Center Innovation Accelerator programme. Over the six-month programme, InnotiveDx refined its US go-to-market strategy with feedback from expert mentors and access to TMC facilities.
• Nature AwardsminorOthersInnotiveDx was longlisted for the Nature Spinoff Prize, a global award for early-stage university spinoffs that turn scientific research into impactful products and services.
• University of LiverpoolcoreStrategic or Co-development PartnerThe company emerged from cutting-edge microbiology research performed at the world-renowned University of Liverpool. Post-doctoral research was conducted at this university.
• University of ManchestercoreStrategic or Co-development PartnerThe company emerged from cutting-edge microbiology research performed at the world-renowned University of Manchester. Co-inventor Dr Srijan Jindal completed his PhD under Professor Douglas Kell at Manchester and is co-inventor of foundational IP.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Specific Diagnostics: Develops the Reveal rapid AST system using proprietary growth-detection sensors to deliver phenotypic AST in hours. Direct peer in rapid phenotypic AST from clinical specimens.
• T2 Biosystems: POC diagnostic company with T2Bacteria and T2Candida panels for direct-from-blood pathogen detection, also addressing the antimicrobial stewardship value proposition. Comparable business model (instrument + consumables, infectious disease focus).
• binx health: Developed the first FDA-cleared/CLIA-waived PCR-based point-of-care test for chlamydia and gonorrhoea. Directly comparable as a POC molecular/rapid infectious disease diagnostics company, and a direct talent pipeline for InnotiveDx (Dr David Pearce and David Whitaker both came from binx).
• Accelerate Diagnostics: Commercializes the Accelerate Pheno system, a rapid identification and AST platform that delivers phenotypic AST results in hours directly from positive blood cultures. Closely comparable use case (rapid bacterial ID + AST) and clinical value proposition around antimicrobial stewardship.
• Q-linea: Swedish IVD company developing the ASTar system for rapid antimicrobial susceptibility testing directly from clinical samples. Highly comparable workflow and target customer (hospital microbiology labs needing fast AST) to InnotiveUTI.

Broad incumbents

• Bruker: Manufacturer of the MALDI Biotyper, a leading microbial identification platform used widely in clinical microbiology labs. Broadly competing for the same clinical microbiology workflow modernization opportunity.
• Beckman Coulter (Danaher): Major incumbent in urine microbiology and clinical diagnostics, including automated urine screening and culture workflows. Broadly competes for the same hospital laboratory and clinical microbiology budget.
• Becton Dickinson (BD): Global medical device and diagnostics incumbent with BD MAX molecular urine panels and urine culture products — overlapping customer base and clinical use case in UTI diagnosis and antimicrobial stewardship.
• bioMérieux: Global leader in clinical microbiology with VITEK mass spectrometry and VITEK 2 AST systems — the incumbent gold standard InnotiveUTI aims to disrupt at the point of care. Comparable end market and customer base.

Others

• Copan Diagnostics: Provider of automated sample-prep and liquid-handling solutions for clinical microbiology, including WASPLab and urine culture automation. Adjacent enabling technology in the same UTI diagnostic workflow.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xlinkedin.com/company/innotivedx/posts/?feedView=all
• LinkedInlinkedin.com/company/innotivedx

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innotive Diagnostics